EU agency says weight-loss drugs risk acceptable

LONDON (Reuters) – The European Medicines Agency has decided that the benefits of orlistat-containing weight loss drugs, including GlaxoSmithKline’s Alli and Roche’s Xenical, outweigh the risk of very rare liver-related side effects.